Hyun Cheol Chung
YOU?
Author Swipe
View article: Evaluating the service readiness of a Paraguay public healthcare center for the primary healthcare system using the WHO SARA tool
Evaluating the service readiness of a Paraguay public healthcare center for the primary healthcare system using the WHO SARA tool Open
This study demonstrates that merely implementing health system-related policies, such as national health plans or service coverage mandates, is insufficient without targeted strategies addressing health workforce distribution, resource all…
View article: Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer Open
Larotrectinib demonstrated long durability, extended survival and manageable safety in patients with TRK fusion GI cancer, including those with MSI-H CRC. This supports the wider adoption of next-generation sequencing testing for NTRK gene…
View article: Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort Open
Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) h…
View article: Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study Open
Background Novel treatments are needed for patients with advanced, triple‐negative breast cancer (TNBC) that progresses or recurs after first‐line treatment with chemotherapy. The authors report results from the TNBC cohort of the multicoh…
View article: Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13) Open
Purpose Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4. We present a phase Ib/II study of a combinatio…
View article: P1187 Persistence of Advanced Therapies in Patients with Inflammatory Bowel Disease: Retrospective cohort study using large healthcare claims database in Japan
P1187 Persistence of Advanced Therapies in Patients with Inflammatory Bowel Disease: Retrospective cohort study using large healthcare claims database in Japan Open
Background Inflammatory bowel disease (IBD) is a lifelong disease and strategically utilizing advanced therapies is essential. Few studies exist to inform the drug utilization of biologics or JAK inhibitors in Japan. The objective is to de…
View article: Validation of a targeted sequencing panel with automatic analysis system for clinical decision support in cancer therapy
Validation of a targeted sequencing panel with automatic analysis system for clinical decision support in cancer therapy Open
Purpose Precision cancer therapy relies on the identification of tumor-specific genomic alterations, which can be achieved through next-generation sequencing (NGS). In the clinic, personalized treatment for patients with advanced treatment…
View article: Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response Open
Evidence on whether prior antibiotic (pATB) administration modulates outcomes of programmed cell death protein-1 (PD-1) inhibitors in advanced gastric cancer (AGC) is scarce. In this study, we find that pATB administration is consistently …
View article: First-in-Human Phase 1 Study of a B Cell– and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer
First-in-Human Phase 1 Study of a B Cell– and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer Open
Purpose BVAC-B is an autologous B cell– and monocyte-based immunotherapeutic vaccine that contains cells transfected with a recombinant human epidermal growth factor receptor 2 (HER2) gene and loaded with the natural killer T cell ligand a…
View article: Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer Open
PURPOSE Trastuzumab-containing chemotherapy is the recommended first-line regimen for human epidermal growth factor receptor 2 (HER2)–positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. We evaluated the safety and effica…
View article: Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial Open
Background In the randomized, controlled, phase III KEYNOTE-061 trial, second-line pembrolizumab did not significantly prolong overall survival (OS) versus paclitaxel in patients with PD-L1-positive (combined positive score ≥1) advanced ga…
View article: Supplementary Figure 4 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Supplementary Figure 4 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression Open
Supplementary Figure 4: In vivo treatment of RAV-18.
View article: Supplementary Data. from <i>HER2</i> Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
Supplementary Data. from <i>HER2</i> Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib Open
Supplementary Data: List of TRIO investigators, Supplementary Materials and Methods, Supplementary Results, Supplementary Discussion, Supplementary References, Supplementary Tables, and Supplementary Figures.
View article: Supplementary Figure 2 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Supplementary Figure 2 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression Open
Supplementary Figure 2: Efficiency of siRNA transfection against ADAM-9, -10 and -17 in 3 gastric cancer cells.
View article: Supplementary Data. from <i>HER2</i> Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
Supplementary Data. from <i>HER2</i> Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib Open
Supplementary Data: List of TRIO investigators, Supplementary Materials and Methods, Supplementary Results, Supplementary Discussion, Supplementary References, Supplementary Tables, and Supplementary Figures.
View article: Supplementary Figure 1 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Supplementary Figure 1 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression Open
Supplementary Figure 1: Transcription level of ADAM9 in gastric cancer cell lines.
View article: Supplementary Figure 3 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Supplementary Figure 3 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression Open
Supplementary Figure 3: Adhesion assay after treatment of RAV-18.
View article: Supplementary Figure 5 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Supplementary Figure 5 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression Open
Supplementary Figure 5: The specificity of RAV-18 to ADAM-9 protease activity
View article: Supplementary Figure 3 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Supplementary Figure 3 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression Open
Supplementary Figure 3: Adhesion assay after treatment of RAV-18.
View article: Supplementary Figure 5 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Supplementary Figure 5 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression Open
Supplementary Figure 5: The specificity of RAV-18 to ADAM-9 protease activity
View article: Supplementary Figure Legends from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Supplementary Figure Legends from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression Open
Supplementary Figure Legends